TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25990379

Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB)
Number of subjects: 30
Study: 24741361

Group type: EXPERIMENTAL
Intervention: 21 days of bed rest (BR)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: 4 days of normal daily activity after 21 days of bed rest
Number of subjects: 7
Study: 22512878

Group type: EXPERIMENTAL
Intervention: Intravenous glutamine (0.5 g/kg/die for 7 days)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Normal amino acid solution (same quantity for 7 days)
Number of subjects: 45
Study: 19879725

Group type: EXPERIMENTAL
Intervention: 26-mm zirconia heads
Number of subjects: 102

Group type: COMPARATOR
Intervention: 26-mm cobalt-chromium heads
Number of subjects: 102
Study: 17943348

Group type: EXPERIMENTAL
Intervention: Uterine artery embolization (UAE)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Myomectomy
Number of subjects: 121
Study: 16105865

Group type: EXPERIMENTAL
Intervention: Urinary Albumin Concentration (UAC)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Urinary Albumin-to-Creatinine Ratio (UACR)
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Micral-Test II
Number of subjects: 278

Group type: EXPERIMENTAL
Intervention: Cost of diagnosing microalbuminuria
Number of subjects: 278
Study: 12356219

Group type: EXPERIMENTAL
Intervention: Topical mupirocin
Number of subjects: 62

Group type: COMPARATOR
Intervention: Topical terbinafine
Number of subjects: 62
Study: 10690158

Group type: EXPERIMENTAL
Intervention: Wheat bran biscuits (6 per day)
Number of subjects: 19
Study: 9095813

Group type: EXPERIMENTAL
Intervention: Low-air loss (LAL) therapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study: 1743336

Group type: COMPARATOR
Intervention: Intrauterine insemination using processed fresh semen (Group A)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intrauterine insemination using the best available cryopreserved semen samples pooled with fresh samples (Group B)
Number of subjects: 150
Study: 6352654

Group type: EXPERIMENTAL
Intervention: Ceftazidime (0.5 g every 12 h)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Tobramycin (3 mg/kg/day)
Number of subjects: 62
Study: 29945203

Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 4 weeks (IXEQ4W)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Ixekizumab 80 mg every 2 weeks (IXEQ2W)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every 2 weeks (ADA)
Number of subjects: 417

Group type: COMPARATOR
Intervention: Placebo (PBO)
Number of subjects: 417

Group type: EXPERIMENTAL
Intervention: Ixekizumab (IXEQ4W and IXEQ2W)
Number of subjects: 417
Study: 26593858

Group type: EXPERIMENTAL
Intervention: Resistance training (RT) 3 days per week for 16 weeks
Number of subjects: 39

Group type: COMPARATOR
Intervention: Control group (usual care)
Number of subjects: 39
Study: 24131447

Group type: EXPERIMENTAL
Intervention: Narrowband ultraviolet B phototherapy (3 times a week for 2 weeks)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (prior pruritus treatment)
Number of subjects: 42
Study: 22244829

Group type: EXPERIMENTAL
Intervention: High-risk group (AFP < 100 ng/mL, PRETEXT IV, vascular invasion, extra-hepatic intra-abdominal disease, metastases)
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Standard-risk group (PRETEXT I/II/III, no other factors)
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: High-risk group (PRETEXT IV, multifocal tumour, age > 5 years, AFP > 1.2 × 10(6) ng/mL)
Number of subjects: 541
Study: 20367555

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 290

Group type: COMPARATOR
Intervention: Conventional medical treatment
Number of subjects: 290
Study: 18791426

Group type: EXPERIMENTAL
Intervention: Short-term psychodynamic supportive psychotherapy
Number of subjects: 81
Study: 16202678

Group type: EXPERIMENTAL
Intervention: Distraction osteogenesis
Number of subjects: 20

Group type: COMPARATOR
Intervention: Rigid osteotomy healing
Number of subjects: 20

Group type: COMPARATOR
Intervention: Comparison between distraction osteogenesis and rigid osteotomy
Number of subjects: 20
Study: 11856128

Group type: EXPERIMENTAL
Intervention: Serum amyloid A (SAA)
Number of subjects: 246

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 246

Group type: COMPARATOR
Intervention: Control group (acute abdominal pain)
Number of subjects: 246
Study: 10432408

Group type: EXPERIMENTAL
Intervention: L-arginine (ARG) supplementation (0.2 g/kg body wt/day) for six months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control vehicle (CRF-C)
Number of subjects: 0
Study: 7997564

Group type: EXPERIMENTAL
Intervention: MR imaging at 1.5 T
Number of subjects: 132

Group type: COMPARATOR
Intervention: MR imaging at 0.5 T
Number of subjects: 132
Study: 2331951

Group type: EXPERIMENTAL
Intervention: Antacid gel (buffering capacity 70 meq/10 ml)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Protein pancake
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Carbohydrate pancake
Number of subjects: 10
Study: 44907

Group type: EXPERIMENTAL
Intervention: amoxycillin
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: cefaclor
Number of subjects: 28
Study: 30550821

Group type: EXPERIMENTAL
Intervention: CD-TREAT
Number of subjects: 5
Study: 28241420

Group type: EXPERIMENTAL
Intervention: Genistein aglycone (54 mg/day)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Calcium (1000 mg) and vitamin D3 (800 IU) - placebo
Number of subjects: 121
Study: 25788034

Group type: EXPERIMENTAL
Intervention: Gemcitabine (GEM)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: S-1
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Gemcitabine plus S-1 (GS)
Number of subjects: 3
Study: 23962782

Group type: EXPERIMENTAL
Intervention: Tele-accelerometry (monthly 6MWTs)
Number of subjects: 155
Study: 21241726

Group type: EXPERIMENTAL
Intervention: Stress condition
Number of subjects: 42

Group type: COMPARATOR
Intervention: Rest condition
Number of subjects: 42
Study: 19903804

Group type: EXPERIMENTAL
Intervention: HPV DNA screening with cytology triage
Number of subjects: 108425

Group type: COMPARATOR
Intervention: Conventional cytology screening
Number of subjects: 108425
Study: 17308315

Group type: EXPERIMENTAL
Intervention: Nordic walking for 45 min three times a week for 12 weeks
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 21
Study: 15114908

Group type: EXPERIMENTAL
Intervention: Negative outcomes with early warning signals
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Negative outcomes without early warning signals
Number of subjects: 83

Group type: COMPARATOR
Intervention: Positive outcomes
Number of subjects: 83
Study: 11299430

Group type: EXPERIMENTAL
Intervention: Lysine clonixinate (LC)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 11084116

Group type: EXPERIMENTAL
Intervention: Right ventricular pacing
Number of subjects: 42

Group type: COMPARATOR
Intervention: Biventricular pacing
Number of subjects: 42

Group type: COMPARATOR
Intervention: Left ventricular pacing
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Paced QRS width shortening
Number of subjects: 42

Group type: COMPARATOR
Intervention: Intrinsic QRS width
Number of subjects: 42

Group type: COMPARATOR
Intervention: Intrinsic QRS width comparison between coronary artery disease and dilated cardiomyopathy
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Overall conclusion
Number of subjects: 42
Study: 8818604

Group type: EXPERIMENTAL
Intervention: Current smokers
Number of subjects: 2569

Group type: EXPERIMENTAL
Intervention: Former smokers
Number of subjects: 2569

Group type: EXPERIMENTAL
Intervention: Ever smokers
Number of subjects: 2569

Group type: EXPERIMENTAL
Intervention: < 5 cigarettes per day
Number of subjects: 2569

Group type: EXPERIMENTAL
Intervention: 5-14 cigarettes per day
Number of subjects: 2569

Group type: EXPERIMENTAL
Intervention: 15-24 cigarettes per day
Number of subjects: 2569

Group type: EXPERIMENTAL
Intervention: >= 25 cigarettes per day
Number of subjects: 2569

Group type: EXPERIMENTAL
Intervention: Former smokers < 3 years since stopping smoking
Number of subjects: 2569

Group type: EXPERIMENTAL
Intervention: Former smokers 3-6 years since stopping smoking
Number of subjects: 2569

Group type: EXPERIMENTAL
Intervention: Former smokers 7-15 years since stopping smoking
Number of subjects: 2569

Group type: EXPERIMENTAL
Intervention: Former smokers >= 16 years since stopping smoking
Number of subjects: 2569
Study: 1602293

Group type: EXPERIMENTAL
Intervention: Ketoprofen (100 mg suppository)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ergotamine (2 mg suppository)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 6608203

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Femoxetine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31029046

Group type: EXPERIMENTAL
Intervention: Probiotic mixture of Bifidobacterium longum Bar33 and Lactobacillus helveticus Bar13 (1:1)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Placebo (no probiotics)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Probiotic mixture of Bifidobacterium longum Bar33 and Lactobacillus helveticus Bar13 (1:1) in aged Balb/c mice
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control mice (placebo)
Number of subjects: 98
Study: 28338531

Group type: EXPERIMENTAL
Intervention: Finasteride
Number of subjects: 6117

Group type: EXPERIMENTAL
Intervention: Oral Contraceptives
Number of subjects: 6117
Study: 27353769

Group type: EXPERIMENTAL
Intervention: HAnOX-M (HA 31mg/2ml + mannitol 70mg/2ml)
Number of subjects: 205

Group type: COMPARATOR
Intervention: Bio-HA (HA 20mg/2ml)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: HAnOX-M
Number of subjects: 205

Group type: COMPARATOR
Intervention: Bio-HA
Number of subjects: 205
Study: 24691217

Group type: EXPERIMENTAL
Intervention: Two-week physiotherapy programme with repetitive exercises of cueing and movement strategies
Number of subjects: 22

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 22
Study: 22943847

Group type: EXPERIMENTAL
Intervention: Suture Capsulorrhaphy (SC)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Suture Anchor Capsulorrhaphy (SAC)
Number of subjects: 12
Study: 20152022

Group type: EXPERIMENTAL
Intervention: Mouthwash containing chlorine dioxide (ClO2)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo mouthwash (without ClO2)
Number of subjects: 15
Study: 17441414

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy with carbamylated allergoid (SLIT)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Pharmacotherapy
Number of subjects: 56
Study: 15610945

Group type: EXPERIMENTAL
Intervention: psychotherapy plus mirtazapine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: psychotherapy plus venlafaxine
Number of subjects: 60

Group type: COMPARATOR
Intervention: psychotherapy (control group)
Number of subjects: 60
Study: 11878657

Group type: EXPERIMENTAL
Intervention: LMA5 (size 5 LMA with a 7.0 mm nasal RAE tube)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: ILM (intubating laryngeal mask with an 8.0 mm special reinforced tracheal tube)
Number of subjects: 80

Group type: COMPARATOR
Intervention: LMA3/4 (size 3 or 4 LMA with a 6.0 mm nasal RAE tracheal tube)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Patil group (endoscopy mask with a 7.5 mm standard tracheal tube)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Patil group
Number of subjects: 80
Study: 9489271

Group type: EXPERIMENTAL
Intervention: Current cocaine dependence
Number of subjects: 518

Group type: EXPERIMENTAL
Intervention: Current cocaine, sedative, or alcohol dependence
Number of subjects: 518
Study: 7603217

Group type: EXPERIMENTAL
Intervention: 2% lignocaine gel
Number of subjects: 80

Group type: COMPARATOR
Intervention: K-Y gel (placebo)
Number of subjects: 80
Study: 2085584

Group type: EXPERIMENTAL
Intervention: Surfactant treated catheter
Number of subjects: 86

Group type: COMPARATOR
Intervention: Untreated control catheter
Number of subjects: 86
Study: 31790968

Group type: EXPERIMENTAL
Intervention: Clear commitment condition
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Unclear commitment condition
Number of subjects: 80
Study: 31111344

Group type: EXPERIMENTAL
Intervention: Formulite™
Number of subjects: 69

Group type: COMPARATOR
Intervention: Optifast™
Number of subjects: 69
Study: 28537354

Group type: EXPERIMENTAL
Intervention: Active TENS device
Number of subjects: 116

Group type: COMPARATOR
Intervention: Placebo TENS device
Number of subjects: 116
Study: 25829377

Group type: EXPERIMENTAL
Intervention: Physical exercise (stationary biking) for 6 months
Number of subjects: 81

Group type: COMPARATOR
Intervention: Life-as-usual (control group)
Number of subjects: 81
Study: 22290823

Group type: EXPERIMENTAL
Intervention: Brief dyadic intervention (three-session)
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Extensive dyadic intervention (six-session)
Number of subjects: 484

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 484
Study: 20584525

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (1,050 mg/d of eicosapentaenoic acid (EPA) and 150 mg/d of docosahexaenoic acid (DHA))
Number of subjects: 432

Group type: COMPARATOR
Intervention: Matched sunflower oil placebo (2% fish oil)
Number of subjects: 432
Study: 19861864

Group type: EXPERIMENTAL
Intervention: 100 gm of dates (Rothana and Sukari) ingested on two separate dialysis sessions
Number of subjects: 9

Group type: COMPARATOR
Intervention: 20 meq of KCl
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Combination of two types of dates
Number of subjects: 9
Study: 16903603

Group type: EXPERIMENTAL
Intervention: Red-hot needle therapy
Number of subjects: 600

Group type: COMPARATOR
Intervention: Filiform needle therapy
Number of subjects: 600
Study: 15023569

Group type: EXPERIMENTAL
Intervention: Serotonin‐1A receptor binding in patients with schizophrenia
Number of subjects: 11

Group type: COMPARATOR
Intervention: Healthy control subjects (22 age-matched and gender-matched)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Correlation of serotonin‐1A receptor binding with symptoms
Number of subjects: 11
Study: 11207993

Group type: EXPERIMENTAL
Intervention: High-frequency oscillatory ventilation (HFOV)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional mechanical ventilation (CMV)
Number of subjects: 30
Study: 9220237

Group type: EXPERIMENTAL
Intervention: Diclofenac sodium 0.1% ophthalmic solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8193487

Group type: EXPERIMENTAL
Intervention: Oral vitamin K1 (2 mg)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Intramuscular vitamin K1 (1 mg)
Number of subjects: 176

Group type: COMPARATOR
Intervention: Comparison of oral vs intramuscular vitamin K1
Number of subjects: 176
Study: 3073933

Group type: EXPERIMENTAL
Intervention: Intravenous imipenem (Group 1)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Standard therapy (Group 2)
Number of subjects: 35
Study: 31099036

Group type: EXPERIMENTAL
Intervention: Biting endurance exercises controlled by biofeedback
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo (simulated laser therapy)
Number of subjects: 46
Study: 29072885

Group type: EXPERIMENTAL
Intervention: Cardiopulmonary ultrasound (CPUS) examination
Number of subjects: 180

Group type: COMPARATOR
Intervention: Control group (no CPUS examination)
Number of subjects: 180
Study: 25526373

Group type: EXPERIMENTAL
Intervention: Endotoxin/lipopolysaccharide (LPS) 0.1 ng/kg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Endotoxin/lipopolysaccharide (LPS) 0.25 ng/kg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Endotoxin/lipopolysaccharide (LPS) 0.5 ng/kg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Endotoxin/lipopolysaccharide (LPS) 1.0 ng/kg
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Endotoxin/lipopolysaccharide (LPS) 2.0 ng/kg
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 25
Study: 23289919

Group type: EXPERIMENTAL
Intervention: Nurse-led follow-up intervention focusing on blood pressure and lipid control, tobacco use, and physical activity.
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care (control group).
Number of subjects: 200
Study: 21656308

Group type: EXPERIMENTAL
Intervention: Morphine (10 mg IM) and Neostigmine (1 mg IM)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Secretin (1 U/kg IV)
Number of subjects: 10
Study: 18432395

Group type: EXPERIMENTAL
Intervention: Combined endurance and muscle strength training
Number of subjects: 285
Study: 17137514

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) using a reciprocating platform at frequencies lower than 20 Hz, 12.6 Hz frequency, 3 cm amplitude, 60 degrees of knee flexion, 3 sessions per week for 8 months
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Walking group, 55 minutes of walking and 5 minutes of stretching, 3 sessions per week for 8 months
Number of subjects: 28
Study: 12765311

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids (low or moderate dose administered in two daily doses)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids in conjunction with prednisone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Low doses of inhaled corticosteroids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0
Study: 10872704

Group type: EXPERIMENTAL
Intervention: Warfarin (therapeutic INR 2.8-4.2)
Number of subjects: 3606

Group type: EXPERIMENTAL
Intervention: 160 mg Aspirin daily
Number of subjects: 3606

Group type: EXPERIMENTAL
Intervention: 75 mg Aspirin daily combined with Warfarin (INR 2.0-2.5)
Number of subjects: 3606
Study: 8636903

Group type: EXPERIMENTAL
Intervention: High self‐handicappers who did not practice much
Number of subjects: 0

Group type: COMPARATOR
Intervention: High self‐handicappers who practiced a lot
Number of subjects: 0
Study: 1317928

Group type: EXPERIMENTAL
Intervention: Oat products (3 g or more of soluble fiber)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Wheat control groups
Number of subjects: 20
Study: 6469082

Group type: EXPERIMENTAL
Intervention: Pentagastrin infusion test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pentagastrin infusion test with cimetidine (200 mg bolus after one hour)
Number of subjects: 0
Study: 30005329

Group type: EXPERIMENTAL
Intervention: Sucralose (200 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 27285466

Group type: EXPERIMENTAL
Intervention: Apremilast 30 mg, administered twice daily for 9 doses
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Apremilast 50 mg, administered twice daily for 9 doses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg, administered as a positive control
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo, used as a control
Number of subjects: 0
Study: 25646746

Group type: EXPERIMENTAL
Intervention: PEG hydrogel spinal sealant
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard of care methods
Number of subjects: 98
Study: 23277436

Group type: EXPERIMENTAL
Intervention: Ventilated on CPB (VG)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-ventilated on CPB (NVG)
Number of subjects: 30
Study: 21119523

Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified porridge flour (rich level of micronutrients)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Basal level of micronutrients in porridge flour
Number of subjects: 125

Group type: EXPERIMENTAL
Intervention: Micronutrient-fortified food (both groups)
Number of subjects: 125
Study: 19042325

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy (CBT) in 9 weekly group sessions
Number of subjects: 177
Study: 17158421

Group type: EXPERIMENTAL
Intervention: Rye bread and pasta (RPa) diet
Number of subjects: 74

Group type: COMPARATOR
Intervention: Oat, wheat bread, and potato (OWPo) diet
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Combined group
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: RPa diet
Number of subjects: 74
Study: 15277619

Group type: EXPERIMENTAL
Intervention: PCV (procarbazine, 60 mg/m2 on days 8 to 21; CCNU, 110 mg/m2 on day 1; and vincristine, 1.4 mg/m2 on days 8 and 29)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Temozolomide (TMZ; 150 to 200 mg/m2 for 5 days every 4 weeks)
Number of subjects: 63
Study: 10969645

Group type: EXPERIMENTAL
Intervention: Complete Mediastinal Lymph Node Dissection (MLND)
Number of subjects: 373

Group type: COMPARATOR
Intervention: Systematic Sampling (SS)
Number of subjects: 373

Group type: EXPERIMENTAL
Intervention: Complete MLND (right lung tumors)
Number of subjects: 373

Group type: COMPARATOR
Intervention: Systematic Sampling (right lung tumors)
Number of subjects: 373
Study: 9343629

Group type: EXPERIMENTAL
Intervention: Computer-assisted instruction
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (no computer-assisted instruction)
Number of subjects: 60
Study: 8445422

Group type: COMPARATOR
Intervention: FEC every 4 weeks
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: FEC weekly
Number of subjects: 173
Study: 2878131

Group type: EXPERIMENTAL
Intervention: Ileu‐ANP infusion (5 micrograms/min for 4 h)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 7
Study: 29333595

Group type: EXPERIMENTAL
Intervention: Closed-loop gastric electrical stimulation (CLGES) system
Number of subjects: 47
Study: 26774608

Group type: EXPERIMENTAL
Intervention: Aliskiren 300 mg per day
Number of subjects: 8561

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8561
Study: 25139724

Group type: EXPERIMENTAL
Intervention: Intrauterine administration of 5 cc of 2% lidocaine
Number of subjects: 67

Group type: COMPARATOR
Intervention: Paracervical block with saline placebo
Number of subjects: 67
Study: 22873367

Group type: EXPERIMENTAL
Intervention: Routine fertility work-up with additional (SIS and) hysteroscopy with on-the-spot treatment of predefined intrauterine abnormalities
Number of subjects: 700

Group type: COMPARATOR
Intervention: Regular fertility work-up without additional diagnostic tests
Number of subjects: 700

Group type: EXPERIMENTAL
Intervention: Routine fertility work-up with additional (SIS and) hysteroscopy
Number of subjects: 700
Study: 20152247

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg/day
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16